Increase in cyclic AMP levels by relaxin in newborn rhesus monkey uterus cell culture.
A novel relaxin sensitive cell line of apparent smooth muscle origin has been established from a newborn rhesus monkey uterus (NRMU). NRMU cells respond to relaxin, in the presence of 1 microM forskolin, by producing intracellular adenosine 3', 5'-cyclic monophosphate (cAMP). The increase in cAMP levels is dose, time and cell density dependent, reaching peak levels at 10 min when cells are seeded at 1 X 10(5) cells/well. Specificity was demonstrated by neutralization of the relaxin activity with anti-relaxin monoclonal and polyclonal antibodies, degradation of cAMP in the presence of phosphodiesterase, and confirmation of the absence of cGMP. Three synthetic analogs of human relaxin generated a dose-related cAMP response as did synthetic native human relaxin. Natural relaxin purified from human corpora lutea tissue also generated a response similar to synthetic human relaxin. Porcine and rat relaxins also increased levels of cAMP. Insulin, but not IGF I or IGF II, was capable of increasing cAMP levels in NRMU cells, however, 200 ng/mL were required to achieve cAMP levels comparable to 6.25 ng/ml relaxin. Combinations of relaxin with insulin, IGF I or IGF II did not increase cAMP levels above levels obtained with relaxin alone. The effect on NRMU cells of other hormones, growth factors and drugs potentially present in cell culture systems or serum samples was evaluated. In combination with relaxin, oxytocin significantly decreased the cAMP production below the levels induced by relaxin alone, whereas progesterone and prostaglandin E2 resulted in additive increases in cAMP. These data suggest that the NRMU cell line is an appropriate target tissue for studying relaxin-mediated biological responses in vitro as well as functioning as the primary component of a relaxin in vitro bioassay.
Kramer
S M
SM
Department of Assay Development, Genentech, Inc., South San Francisco, California 94080.
Gibson
U E
UE
Fendly
B M
BM
Mohler
M A
MA
Drolet
D W
DW
Johnston
P D
PD
D000199:Actins / Q000032:analysis; D000527:Alprostadil / Q000494:pharmacology; D000818:Animals; D000831:Animals, Newborn; D000906:Antibodies; D000911:Antibodies, Monoclonal; D002460:Cell Line; D002478:Cells, Cultured; D005576:Colforsin / Q000494:pharmacology; D000242:Cyclic AMP / Q000378:metabolism*; D005260:Female; D007328:Insulin / Q000494:pharmacology; D007334:Insulin-Like Growth Factor I / Q000494:pharmacology; D007335:Insulin-Like Growth Factor II / Q000494:pharmacology; D008253:Macaca mulatta; D011994:Recombinant Proteins / Q000494:pharmacology; D012065:Relaxin / Q000494:pharmacology*; D014599:Uterus / Q000187:drug effects / Q000378:metabolism*
D000199:Actins; D000906:Antibodies; D000911:Antibodies, Monoclonal; D007328:Insulin; D011994:Recombinant Proteins; D005576:Colforsin; D007334:Insulin-Like Growth Factor I; D007335:Insulin-Like Growth Factor II; D012065:Relaxin; D000242:Cyclic AMP; D000527:Alprostadil